. The C-terminal tail of polycystin-1 regulates complement factor B expression by signal transducer and activator of transcription 1. Am J Physiol Renal Physiol 310: F1284 -F1294, 2016. First published March 16, 2016 doi:10.1152/ajprenal.00428.2015.-Inhibition of the overactivated alternative complement pathway in autosomal dominant polycystic kidney disease (ADPKD) retards disease progression in animal models; however, it remains unknown how complement factor B (CFB) is upregulated in ADPKD. Here, we showed that the overexpression of CFB in cystic kidneys is associated with increased JAK2/STAT1 activity and enhanced expression of the polycystin-1 C-terminal tail (PC1-CTT). Overexpression or blockage of STAT1 increased or decreased CFB expression and CFB promoter activity. Moreover, overexpression of PC1-CTT induced JAK2/STAT1 activation and CFB upregulation in renal tubular epithelial cells. Furthermore, PC1-CTT overexpression increased human CFB promoter activity, whereas dominant negative STAT1 plasmids or mutation of putative STAT1 responsive elements decreased PC1-CTT-induced CFB promoter activity. The effect of CFB on macrophage differentiation was tested on a mouse macrophage cell line. Bioactive CFB dose dependently promoted macrophage M2 phenotype conversion. In addition, conditioned media from renal epithelial cells promoted macrophage M2 phenotype conversion which was blocked by STAT1 inhibition in a dose-dependent manner. Conditioned media from PC1-CTT-transfected renal epithelial cells further promoted macrophage M2 phenotype conversion, which was suppressed by fludarabine or a CFB antibody. In addition, we show that NF-B acts downstream of PC1-CTT and may partly mediate PC1-CTT-induced CFB expression. In conclusion, our study reveals possible mechanisms of CFB upregulation in ADPKD and a novel role of PC1-CTT in ADPKD-associated inflammation. Furthermore, our study suggests that targeting STAT1 may be a new strategy to prevent inflammation in the kidney of patients with ADPKD.
kidney; complement; macrophage; polycystic kidney disease (PKD); polycystin-1 C-terminal tail (PC1-CTT); Janus kinase 2 (JAK2); signal transducer and activator of transcription 1 (STAT1) AUTOSOMAL DOMINANT POLYCYSTIC kidney disease (ADPKD) is one of the leading causes of end-stage renal failure (21) . Most cases of ADPKD (85%) are caused by mutations in the PKD1 gene which encodes polycystin-1. Polycystin-1 is a large transmembrane protein containing a ϳ200-amino acid cytoplasmic tail which can be cleaved into a full-length 30-kDa peptide and a half-length 15-kDa peptide upon mechanical stimulation (4, 18) . The 30-kDa peptide (PC1-CTT) is overexpressed in AD-PKD and nonorthologous models of polycystic kidney disease (PKD) (18) . PC1-CTT plays important roles in cell proliferation, apoptosis, and polarity (2, 8, 18) . Moreover, overexpression of PC1-CTT induced renal cysts in the zebrafish model (9) . As a cotranscriptional factor, PC1-CTT regulates multiple downstream signaling pathways such as the JAK-signal transducer and activator of transcription (STAT) pathway (18) . The JAK2/STAT1 pathway plays multiple roles in tumor genesis (1, 5) . Among STAT family members, only STAT1, STAT3, and STAT6 have been studied in the field of PKD (19) . STAT3 and STAT6 displayed proliferative and procystic effects in animal models of PKD (10, 17) . In vitro studies showed that STAT1 mediates polycystin-1-induced cell cycle arrest; however, STAT1 promotes tumor growth mainly through its proinflammatory property, but this has not yet been studied in PKD (1, 3, 5) .
The role of inflammation in PKD has gained increasing attention in recent years (16) . Inflammatory cells such as macrophages accumulate in polycystic kidney tissues in proximity to renal cysts and differentiate into an M2 phenotype. This could be triggered by undefined soluble factors which are secreted by the cystic epithelium (15) .
We have previously shown that the alternative complement pathway is aberrantly activated in PKD and that rosmarinic acid retards PKD progression. This is associated with decreased complement factor B (CFB) expression and reduced infiltration of macrophages (13, 14) . However, the underlying mechanisms of alternative complement pathway activation in polycystic kidneys in PKD remain unclear.
The purpose of this study was to explore the mechanism of CFB overexpression in PKD and to investigate whether polycystin-1 regulates CFB expression.
MATERIALS AND METHODS
Reagents and plasmids. The 712-bp human CFB promoter was subcloned into the pGL3-basic luciferase reporter vector. The site mutation of STAT1 response element on the CFB promoter plasmid was made using the Fast mutagenesis system (Transgen, Beijing, China). The sixfold repeated GAS (5=-TTCCGGGAA-3=) sequence and sixfold repeated and mutated GAS (5=-CGTACGGCT-3=) sequence were constructed on the pGL3-basic vector. The vector pRL-TK was obtained from Promega (Madison, WI). PC1-CTT, dominant negative (DN)-1-STAT1 (mutation at Y701F), and DN-2-STAT1 (mutation at S727A) plasmids were obtained from Addgene (18, 20) . STAT1 was subcloned into the pCDNA4/TO-mycHis vector.
Total STAT1 (9172), p-JAK2 (3776), and p-STAT1 (7649) antibodies were from Cell Signaling Technology (Beverly, MA). The GAPDH antibody (sc-365062), PC1 C-terminal antibody (sc-10371), and control rabbit IgG (sc-2027) were from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-myc was from Abmart (M20002, Shanghai, China). The CFB antibodies were from Proteintech (10170-1-AP; Chicago, IL) and Santa Cruz Biotechnology (H95, sc-67141). Arginase-1 (ab60176) and inducible nitric oxide synthase (iNOS; ab3523) antibodies were from Abcam (Cambridge, UK). The STAT1-specific inhibitor fludarabine (S1491) and the NF-B-specific inhibitor QNZ were obtained from Selleckchem (Houston, TX). Bioactive human CFB was purchased from Hycult Biotech (Uden, The Netherlands). IL-4 (241-14) and IL-13 (210-13) were from PeproTech (Rocky Hill, NJ). INF-␥ (PMC4031; GIBCO) was bought from Invitrogen.
Animal and human samples. Rat kidney tissues were collected from the Han:SPRD rat colony established in our animal facility from a litter which was obtained from Prof. R. P. Wuthrich (University of Zurich). Rats were kept according to local regulation and guidelines. Tissue samples from anonymous ADPKD patients and normal controls were obtained from Shanghai Changzheng Hospital. Informed consent was obtained from all participants.
Cell culture and transfection. Pkd1 ϩ/Ϫ and Pkd1 Ϫ/Ϫ cells were obtained from Dr. Yiqiang Cai (Yale University, New Haven, CT) (6) . Human immortalized renal epithelial cells (UCL93) were kindly provided by Prof. A. C. Ong (University of Sheffield, Sheffield, UK) (11) . Cells were cultured to 70 -80% confluence and transfected using Ronfect reagent (Ronbio, Shanghai, China) according to the manufacturer's instructions, for 48 h before protein extraction.
Protein extraction and Western blot analysis. Snap-frozen kidney tissue was homogenized in freshly made tissue protein extraction reagent (T-PER, Pierce Bioscience, Rockford, IL). Homogenates were centrifuged, and supernatants were stored at Ϫ80°C.
To extract cell protein, cultured cells were washed and lysed in the same way. Lysates in SDS-sample buffer were boiled for 5 min at 95°C, and equal protein amounts were resolved by SDS-PAGE gels before being transferred to a polyvinylidene difluoride membrane. The membrane was probed with the first antibody by overnight incubation at 4°C, and thereafter with a secondary antibody by incubation for 2 h at room temperature. Proteins of interest were then visualized by enhanced chemiluminescence detection reagents. The average densitometry values from three independent experiments were measured. Since the blot probed with polycystin-1 antibody had a high background when the standard protocol was used, we used a lower dilution of the first antibody (1:4,000) and the second antibody (1:5,000). In addition, the blot was incubated with the second antibody for only 2 h at 4°C before visualization.
Immunohistochemical analysis. Immunhistochemistry was performed on paraffin sections of formalin-fixed tissues (3-m thick). Sections were incubated overnight at 4°C with primary antibody against p-JAK2 (1:100, ab32101, Abcam), p-STAT1 (1:100, AF3299, Affinity), CFB antibody (1:100, 10170-1-AP, Proteintech) and PC1 C-terminal antibody (1:200, sc-10371, Santa Cruz Biotechnology). Signals were detected using the Dako EnVision Detection Systems Peroxidase/DAB, Rabbit/Mouse (K5007). Micrographs were made randomly using ϫ400 magnification of the light microscope.
Dual-luciferase reporter assay. UCL93 cells were cultured to 70 -80% confluence in a 48-well plate using a Ronfect transfection reagent according to the manufacturer's instructions, using 25 ng reporter construct, 25 ng pRL-TK plasmid, and 50 ng expression plasmid, then cultured for 24 h in starve medium. A dual-luciferase reporter assay system (Promega) was used for measurements of firefly and Renilla luciferase activities. At least three independent transfections were performed, and all analyses were performed in quadruplicate. The average values in each experiment were measured.
Chromatin immunoprecipitation assay. A chromatin immunoprecipitation (ChIP) assay was conducted using a Beyotime-ChIP Assay Kit, according to the manufacturer's protocol (P2078, Beyotime, Nanjing, China). Immunoprecipitation was performed with the antitotal STAT1 antibody. Two PCR primer pairs were designed, one containing a putative STAT-binding site and the other spanning the Ϫ712/Ϫ373 region, representing a nonspecific region of the CFB promoter. PCR products were analyzed by 2.5% agarose/ethidium bromide gel electrophoresis.
In vitro macrophage differentiation assay. UCL93 cells were cultured in DMEM/F12 medium containing 2% FBS in a six-well plate. The medium was changed 16 h after transfection or fludarabine treatment, and then cells were cultured for another 24 h with starvation medium. In some experiments, the STAT1 inhibitor fludarabine was added 6 h after transfection and the medium was changed 16 h after transfection. Cell-free supernatants were named conditioned medium (CM) and stored in aliquots at Ϫ80°C.
Approximately 1 ϫ 10 6 RAW264.7 cells were cultured in 2% FBS medium in a six-well plate overnight before the experiments. The CM from UCL93 cells was used to treat mouse RAW264.7 cells. In some experiments, bioactive human CFB or CFB antibodies were added to unconditioned medium or CM as indicated elsewhere. As positive controls, 100 g/ml IL-4/IL-13 or 100 ng/ml INF-␥ was added to unconditioned medium to induce macrophage differentiation. After 24 h of treatment, protein was extracted and probed for iNOS and arginase-1 using Western blotting as described above.
Real-time PCR. Total RNA was extracted using an RNase minikit (Invitrogen, Carlsbad, CA) and reverse-transcribed. The primer sequences were as follows: arginase-1, forward, 5=-CTCCAAGC-CAAAGTCCTTAGAG; reverse, 5=-GGAGCTGTCATTAGGGA-CATC; iNOS, forward, 5=-GTTCTCAGCCCAACAATACAAGA; reverse, 5=-GTGGACGGGTCGATGTCAC; Mrc1, forward, 5=-CTCTGTTCAGCTATTGGACGC; reverse, 5=-CGGAATTT-CTGGGATTCAGCTTC; and GAPDH, forward, 5=-AGAACAT-CATCCCTGCATCC; reverse, 5=-ATACCAGGAAATGAGCTT-GAC. Real-time PCR was performed using SYBR Green PCR Master Mix (Toyobo, Osaka, Japan) and the Rotor-Gene-3000A real-time PCR system (Corbett, Sydney, Australia) according to the manufacturer's protocol. In brief, the PCR amplification reaction mixture (25 l) contained 1 l cDNA, 0.4 mM sense and antisense primer, and 12.5 l SYBR Green I. After initial denaturation at 95°C for 1 min, the reaction was cycled 45 times. Each cycle consisted of denaturation at 95°C for 15 s, and primer annealing and extension at 60°C for 31 s. The results are given as relative expression of arginase-1, iNOS, and Mrc1 normalized to the expression of GAPDH. Real-time PCR was done in triplicate for each experiment, and the average values were measured. Each experiment was repeated three times.
Statistical analysis. Statistical analyses were performed by unpaired t-test or one-way ANOVA with the Newman-Keuls post hoc test using GraphPad Prism version 5.0 (GraphPad, San Diego, CA). All data are expressed as means Ϯ SD, and P Ͻ 0.05 was considered as statistically significant. Figure 1 , A and B, shows that CFB was upregulated in human and rat cystic kidney tissues, which correlated with increased p-JAK2, p-STAT1, and PC1-CTT.
RESULTS

CFB overexpression correlates with PC1-CTT overexpression and JAK2/STAT1 activation in polycystic kidney tissues.
Immunohistochemistry was performed on rat kidney tissues to confirm the finding by Western blotting. Figure 1C shows that signals for p-JAK2, p-STAT1, CFB, and PC1-CTT were enhanced in Cy/ϩ cystic kidneys, where a similar expression pattern was found for these proteins. All these proteins were strongly stained in dilated tubules and small cysts but were weakly stained in large cysts.
Since the specificity of the commercially available polycystin-1 antibody for PC1-CTT has not been reported, we performed two experiments to test its specificity. Figure 2A shows that PC1-CTT can be detected by this polycystin-1 antibody in Pkd1 ϩ/Ϫ cells but not Pkd1 Ϫ/Ϫ cells. Moreover, overexpression of exogenous PC1-CTT could be detected by the polycystin-1 antibody and also by the myc-tag antibody (Fig. 2B) .
STAT1 regulates CFB expression. To determine whether STAT1 regulates CFB expression in renal epithelial cells, we overexpressed STAT1 plasmids in UCL93 immortalized human renal epithelial cells. Figure 3A shows that overexpression of STAT1 increased CFB expression compared with control cells, which were transfected with empty vectors. Moreover, the STAT1 inhibitor fludarabine dose dependently reduced CFB expression, which correlated with decreased p-STAT1 levels (Fig. 3B) .
The putative STAT1-binding site TTCCGAGAA was identified in the promoter sequence of the human CFB gene, at position Ϫ219 to Ϫ210 upstream of the translation start site (Fig. 4A) . The STAT1 gene, CFB promoter, and Renilla were cotransfected in renal epithelial cells and were assayed for luciferase activity. Renilla values obtained were used for normalization of CFB promoter activity. Empty vector-, CFB promoter-, and Renilla-cotransfected cells were used as a control. STAT1 transfection led to a sixfold increase in promoter activity (Fig. 4B) . Luciferase activity did not increase in cells transfected with STAT1 binding site mutated CFB promoter (Fig. 4B) . It is known that the ␥-interferon activation site (GAS) sequence contains a STAT1 binding site (7). Thus we designed a reporter gene containing six repeated GAS sequences (GAS 5=-TTCCGGGAA-3=) and another reporter gene containing six mutated and repeated GAS sequences (GAS mutation 5=-CGTACGGCT). In Fig. 4C , we show that the CFB reporter gene and GAS reporter gene have similar responses to STAT1 stimulation and that the GAS mutation abolished the response of the GAS reporter gene to STAT1 stimulation.
To confirm the direct association of the STAT1 protein with the human CFB promoter, we performed ChIP assays. The PCR primer pair 1 was designed to flank the potential STAT1 site (Ϫ382 to Ϫ138), and we observed that the STAT1 protein level was increased in this region in STAT1-overexpressed 293T cells compared with empty vector-transfected control cells. The second selected region (Ϫ712 to Ϫ373) was amplified by primer pair 2, which does not contain a STAT1 response element and represents a nonspecific region in the CFB promoter (Fig. 4D) . No STAT1 protein was enriched in the second region.
STAT1 mediates PC1-CTT-induced CFB expression.
To test whether PC1-CTT regulates CFB expression, a soluble PC1-CTT was overexpressed in UCL93 renal epithelial cells. PC1-CTT increased CFB expression, which correlated with enhanced phosphorylation of JAK2 and STAT1 in renal epithelial cells (Fig. 5A) .
We next tested whether the PC1-CTT-induced expression of CFB requires STAT1. PC1-CTT-transfected renal epithelial cells were treated with fludarabine. The STAT1 inhibitor fludarabine suppressed PC1-CTT-induced CFB overexpression and p-STAT1 upregulation in renal epithelial cells (Fig. 5B) .
Mutation of the STAT1 binding site significantly downregulated PC1-CTT-induced CFB promoter activity in UCL93 cells by 29% (Fig. 6A) , which suggests that the STAT1 response element at Ϫ219 to Ϫ210 is important for PC1-CTT-mediated transactivation of CFB promoter.
To further investigate the mechanism of STAT1 regulation of CFB expression, a PC1-CTT plasmid was cotransfected with two different DN STAT1 plasmids (DN1-STAT1 with Y701F mutation or DN2-STAT1 with S727A mutation). DN1-STAT1 and DN2-STAT1 significantly suppressed PC1-CTTinduced CFB promoter activity compared with PC1-CTT and empty vector-cotransfected cells (Fig. 6B) . Furthermore, we showed that the CFB reporter gene and GAS reporter gene have similarly increased responses to PC1-CTT stimulation and that the GAS mutation abolished the response of the GAS reporter gene to PC1-CTT stimulation (Fig. 6C) . Taken together, our data indicate that PC1-CTT is capable of activating CFB transcription through the promoter element in the region Ϫ219 to Ϫ210 which contains the STAT1 binding site.
PC1-CTT stimulates macrophage differentiation through STAT1 and CFB.
To study whether CFB triggers macrophage M2 phenotype differentiation, bioactive human CFB was used to treat RAW264.7 mouse macrophage cells. Figure 7A shows that human CFB dose dependently upregulated the M2 marker arginase-1 in mouse macrophages from 30 to 100 ng/ml, and the expression of M1 phenotype marker iNOS was not changed by CFB stimulation. RT-PCR was performed to further analyze macrophage differentiation. Figure 8A shows that the M2 marker arginase-1 but not Mrc1 was increased by CFB treatment. However, CFB-induced M2 macrophages had lower arginase-1 expression compared with typical M2 macrophages induced by IL-4/IL-13. Again, the mRNA expression of the M1 markers iNOS or TNF-␣ was not upregulated by CFB treatment (Fig. 8B) . Moreover, a CFB antibody was included in Fig. 4 . A: representation of CFB promoter with putative STAT binding site (Ϫ219/Ϫ210). B: luciferase activity of CFB promoter (CFB-Pr) or mutated CFB promoter (CFB-Pr-Mut) was measured in control or STAT1-transfected UCL93 cells. C: luciferase activity of CFB-Pr, GAS promoter (GAS-Pr), or mutated GAS promoter (GAS-Pr-Mut) was measured in control or STAT1-transfected UCL93 cells. D: a chromatin immunoprecipitation (ChIP) assay was conducted of 293T cells transfected with control or STAT1. Two different regions (Ϫ700/Ϫ350, Ϫ400/Ϫ100) were amplified by PCR after ChIP using an anti-STAT1 antibody. One representative of 3 independent experiments is shown. **P Ͻ 0.01. the CM that was generated from renal epithelial cells transfected with PC1-CTT (PC1-CTT-CM). Treatment of RAW264.7 cells with the CM from PC1-CTT-overexpressing renal epithelial cells markedly increased the protein level of arginase-1 but not iNOS, whereas CFB antibody neutralization in PC1-CTT-CM suppressed arginase-1 expression in Raw 264.7 macrophage cells dose dependently (Fig. 7B) . RT-PCR analysis showed that PC1-CTT-CM induced significantly higher expression of the M2 markers arginase-1 and Mrc1, but did not induce M1 macrophage differentiation (Fig. 8, C and  D) . Interestingly, PC1-CTT induced a similar level of arginase-1 expression but less Mrc1 expression compared with IL-4/IL-13-induced M2 macrophages (Fig. 8C) .
To explore the role of STAT1 in renal epithelial cellinduced M2 macrophage differentiation, we generated CM from renal epithelial cells which were treated with the STAT1-specific inhibitor fludarabine. Figure 7C shows that STAT1 inhibition in renal epithelial cells reduced arginase-1 expression by macrophages in a dose-dependent manner. Moreover, STAT1 inhibition by fludarabine in renal epithelial cells suppressed arginase-1 expression induced by PC1-CTT-CM (Fig. 7D) . Taken together, our data suggest that PC1-CTT-induced macrophage activation into an M2 phenotype is mediated by STAT1 and CFB.
NF-B partly mediates PC1-CTT induced CFB expression.
To test whether the NF-B pathway partly mediates PC1-CTT-induced CFB expression, we first treated renal epithelial cells with the NF-B inhibitor 6-amino-4-(4-phenoxypheny lethylamino) (quinazoline; QNZ). Figure 9A shows that QNZ dose dependently downregulated CFB expression, which correlated with downregulation of p50/p65 NF-B. Second, PC1-CTT induced upregulation of p50/p65 NF-B and CFB, and QNZ downregulated p50/p65 and CFB expression (Fig. 9B) . Third, we found that CFB promoter activity triggered by PC1-CTT was reduced by the NF-B inhibitor QNZ (Fig. 9C) .
DISCUSSION
We previously showed that CFB is upregulated and plays an important role in human ADPKD and in the Han:SPRD rat model of PKD; however, the mechanism of CFB overexpression in PKD is not known (13, 14) . Huang et al. (7) showed that STAT1 mediates IFN-␥-induced mouse CFB expression through direct interaction with the murine CFB promoter (7). Therefore, we hypothesized that STAT1 regulates CFB expression in PKD. In this study, we proved this hypothesis by showing that 1) STAT1 activation correlated with CFB expression in rat and human cystic kidney tissues; 2) overexpression of STAT1 in renal epithelial cells increased CFB expression; 3) STAT1 inhibition by fludarabine reduced CFB expression; 4) STAT1 overexpression enhanced CFB promoter activity, and a mutation of the STAT1 binding site on CFB promoter abolished this effect; and 5) STAT1 interacted with the human CFB promoter.
It is known that the cytoplasmic tail of polycystin-1 can be cleaved into a 30-kDa soluble peptide (PC1-CTT) which can function as a cotranscriptional factor entering the cell nucleus and regulating downstream gene expression (2, 4, 18) . Moreover, it was shown that PC1-CTT increases STAT1 transcriptional activity (18) . Therefore, we hypothesized that PC1-CTT upregulates CFB expression through STAT1 in PKD. Here, we showed that the PC1-CTT overexpression correlated with JAK2 and STAT1 activation in human and rat polycystic kidneys where CFB was abnormally upregulated. Second, PC1-CTT overexpression in renal epithelial cell-activated JAK2/STAT1 pathway and led to upregulation of CFB. Finally, STAT1 inhibition abolished PC1-CTT induced CFB expression and CFB promoter activation.
Interestingly, we found that mutation of the STAT1 binding site only partly abolished PC1-CTT-triggered CFB promoter activity, whereas the mutant promoter completely blocked STAT1-induced CFB promoter activation. These data suggest that a fraction of the PC1-CTT effect on CFB promoter is independent of STAT1. It has been shown that NF-B could regulate CFB expression, and that the NF-B pathway is activated in cystic kidneys (12, 16) . We therefore postulated that NF-B could partly mediate PC1-CTT induced CFB expression. We proved this by showing that 1) NF-B inhibitor QNZ downregulated CFB expression in renal epithelial cells; 2) the reporter activity driven by PC1-CTT can be reduced by the NF-B inhibitor QNZ; and 3) PC1-CTT induced upregulation of p50/p65 NF-B and CFB, and moreover QNZ downregulated p50/p65 and CFB expression.
The role of STAT1 in PKD is not completely studied. It has been shown that polycystin-1 induces cell cycle arrest through STAT1 activation, suggesting an antiproliferative and therefore a protective role of STAT1 in PKD (3). However, our data showed that STAT1 mediates PC1-CTT-induced CFB expression and macrophage differentiation in vitro. We further confirmed the correlation of STAT1 activation and CFB expression in human and rat polycystic kidneys. In liver disease, IFN-␥ activation of STAT1 induces apoptosis-associated liver inflammation (5) . Interestingly, in a nonorthologous PKD mouse model, where the PC1 tail is overexpressed, IFN-␥ challenge resulted in a strong STAT1 activation and increased apoptosis level. These data suggest a proinflammatory role of STAT1 in PKD. Therefore, an in vivo study should be per- formed with a STAT1 inhibitor or by STAT1 gene depletion to confirm its role in PKD.
Macrophages which have infiltrated the cystic kidneys present with a special M2 phenotype which is characterized by highly increased arginase-1 expression and slightly increased Mrc1 expression (15) . Our study suggests that PC1-CTT and CFB participate in cystic M2 macrophage differentiation. First, with different M1 or M2 markers and with two different approaches, we showed that PC1-CTT or CFB promoted macrophage M2 but not M1 phenotype conversion. Second, PC1-CTT or CFB stimulated arginase-1 expression but not, or to a lesser degree, Mrc1 expression, which is consistent with the cystic M2 phenotype. Interestingly, compared with IL-4/IL-13-induced conventional M2 macrophages, PC1-CTT stimulated similar levels of arginase-1 expression but decreased levels of Mrc1 expression, whereas CFB-triggered macrophages had much less arginase-1 expression and Mrc1 expression. These data suggest that there are other undefined factors, different from CFB, that participate in PC1-CTT-induced macrophage differentiation. Fig. 7 . PC1-CTT promotes RAW264.7 macrophages toward M2 phenotype differentiation through STAT1 and CFB. A: bioactive human CFB was added to unconditioned media to treat macrophages. The expression of the macrophage M1 phenotype marker inducible nitric oxide synthase (iNOS) and M2 phenotype marker arginase-1 were examined by Western blotting. Blots were quantified by densitometry, and the average densitometry values from 3 independent experiments are shown. B: conditioned media were prepared from control (Control-CM) or PC1-CTT (PC1-CTT-CM)-transfected renal epithelial cells. Isotype IgG or CFB antibody was added to treat macrophages. C: conditioned media were generated from renal epithelial cells treated with fludarabine and used to treat macrophages for 24 h. D: PC1-CTT was transfected in renal epithelial cells and followed by fludarabine treatment, and conditioned media were collected to treat macrophages. One representative of 3 independent experiments is shown. *P Ͻ 0.05. **P Ͻ 0.01. ***P Ͻ 0.001.
The M2 macrophages that infiltrate the cystic kidney may promote cyst expansion by directly or indirectly stimulating cyst epithelial cell proliferation (15, 16) . We showed that conditioned media derived from STAT1-inhibited renal epithelial cells retarded macrophage M2 differentiation. Therefore, STAT1 may also play a proliferative role in ADPKD through activating macrophages.
The overexpression of PC1-CTT is observed in human ADPKD and also in nonorthologous animal models of PKD (18) . Ureteral ligation also induced upregulation of PC1-CTT in nonmutated kidneys, suggesting that alteration of tubular fluid flow triggers the cleavage of the cytoplasmic tail from the mechanical sensor polycystin-1 (4). In this study, we found a novel function of PC1-CTT in PKD inflammation, namely, increased CFB expression in renal epithelial cells and modulated macrophage differentiation. Interestingly, we found PC1-CTT and CFB strongly expressed in small cysts. It has been shown that in ADPKD kidney tissues, macrophages localize mostly adjacent to renal cysts or even infiltrate small cysts (15) . Thus it could be speculated that the change in tubular fluid flow by expanding renal cysts initiates inflammation through increasing cleavage of polycystin-1 and this might lead to the genesis of new cysts.
In summary, our study showed that CFB overexpression in PKD is caused, at least in part, by PC1-CTT-induced STAT1 activation, and by activation of the NF-B pathway. STAT1 could be a new target in preventing PKD inflammation. 
